1. CALHM1 and its polymorphism P86L differentially control Ca2+ homeostasis, mitogen-activated protein kinase signaling, and cell vulnerability upon exposure to amyloid β.
- Author
-
Moreno‐Ortega, Ana José, Buendia, Izaskun, Mouhid, Lamia, Egea, Javier, Lucea, Susana, Ruiz‐Nuño, Ana, López, Manuela G., and Cano‐Abad, María F.
- Subjects
CALCIUM channels ,AMYLOID beta-protein ,HOMEOSTASIS ,MITOGEN-activated protein kinases ,GENETIC overexpression - Abstract
The mutated form of the Ca2+ channel CALHM1 (Ca
2+ homeostasis modulator 1), P86L-CALHM1, has been correlated with early onset of Alzheimer's disease (AD). P86L-CALHM1 increases production of amyloid beta (Aά) upon extracellular Ca2+ removal and its subsequent addback. The aim of this study was to investigate the effect of the overexpression of CALHM1 and P86L-CALHM, upon Aά treatment, on the following: (i) the intracellular Ca2+ signal pathway; (ii) cell survival proteins ERK1/2 and Ca2+ /cAMP response element binding (CREB); and (iii) cell vulnerability after treatment with Aά. Using aequorins to measure the effect of nuclear Ca2+ concentrations ([Ca2+ ]n ) and cytosolic Ca2+ concentrations ([Ca2+ ]c) on Ca2+ entry conditions, we observed that baseline [Ca2+ ]n was higher in CALHM1 and P86L-CALHM1 cells than in control cells. Moreover, exposure to Aά affected [Ca2+ ]c levels in HeLa cells overexpressing CALHM1 and P86L-CALHM1 compared with control cells. Treatment with Aά elicited a significant decrease in the cell survival proteins p-ERK and p-CREB, an increase in the activity of caspases 3 and 7, and more frequent cell death by inducing early apoptosis in P86L-CALHM1- overexpressing cells than in CALHM1 or control cells. These results suggest that in the presence of Aά, P86L-CALHM1 shifts the balance between neurodegeneration and neuronal survival toward the stimulation of pro-cytotoxic pathways, thus potentially contributing to its deleterious effects in AD. [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF